Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): A systematic review and meta-analysis-Reference-Cited by-同舟云学术

Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): A systematic review and meta-analysis

Published:2022-03 Issue: Volume:364 Page:577812
ISSN:0165-5728
Container-title:Journal of Neuroimmunology
language:en
Short-container-title:Journal of Neuroimmunology

Author:

Nepal Gaurav,Kharel Sanjeev,Coghlan Megan Ariel,Rayamajhi Parash,Ojha Rajeev

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,Immunology,Immunology and Allergy

Reference37 articles.

1. Rituximab in children with myelin oligodendrocyte glycoprotein antibody and relapsing neuroinflammatory disease;Albassam;Dev. Med. Child Neurol.,2020

2. Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis;Borisow;Front. Neurol.,2018

3. E.U. paediatric MOG consortium consensus: part 5 - treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders;Bruijstens;Eur. J. Paediatr. Neurol. EJPN Off. J. Eur. Paediatr. Neurol. Soc.,2020

4. Emerging drugs for the treatment of adult MOG-IgG-associated diseases;Carnero Contentti,2021

5. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder;Chen;Neurology.,2020

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic factors associated with disability in a cohort of neuromyelitis optica spectrum disorder and MOG-associated disease from a nationwide Portuguese registry;Journal of the Neurological Sciences;2024-09

2. Unusual demyelinating disease in a patient with HIV infection;Journal of NeuroVirology;2024-08-18

3. Predictors of a relapsing course in myelin oligodendrocyte glycoprotein antibody-associated disease;Journal of Neurology, Neurosurgery & Psychiatry;2024-07-04

4. Rituximab Therapy for Immune-Mediated Neurological Diseases: Our Experience at a Tertiary Care Centre;Cureus;2024-06-12

5. Effectiveness of immunotherapies in relapsing myelin oligodendrocyte glycoprotein antibody-associated disease;Multiple Sclerosis Journal;2024-02-05